spacer
home > ict > summer 2021 > smart home devices foster the next generation of decentralised clinical trials
PUBLICATIONS
International Clinical Trials

Smart Home Devices Foster the Next Generation of Decentralised Clinical Trials


The clinical trial industry is buzzing about digital transformation. Advances in technology are fostering a vision to enhance drug discovery and clinical research. The time has arrived for innovative approaches to engage patients at home in clinical trial research. The pandemic brought about a drastic increase in telehealth virtual visits. Now, in the wake of the COVID-19 pandemic, biopharmaceutical companies are exploring a new model of drug development, engaging patients from their homes with smart, home, digital healthcare devices that dovetail telehealth visits with medication adherence and other clinical data. Many patients experienced the ease and convenience of telehealth visits for the first time during the pandemic. The trend in the industry for increased use of telehealth services and smart home devices for decentralised clinical trials is here to stay, engaging patients from their homes. Telehealth virtual visits give clinical care providers and biopharma clinicians direct access to patients without the need for an in-person office visit.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the Author

Tom Rhoads has been leading the development and launch of healthcare technology for 25 years. He was CEO of Parata Systems, a pharmacy automation company, before deciding to pursue an entrepreneurial path as the founder and CEO of Spencer Health Solutions, a spin-off from Parata Systems, headquartered in North Carolina’s Research Triangle Park region, US. Rhoads led the development of Spencer Health Solutions products and services centred on patients and caregivers. Prior to his role at Parata Systems, Rhoads held leadership roles at Baxter Healthcare and Cardinal Health Corporation.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Emmes launches Orphan Reach™: Emmes’ Rare Disease Center

03rd November, 2021, Rockville, Maryland (USA): Emmes – a full service, global clinical research organization (CRO) – is launching its new center, Orphan Reach™ as a unique ‘rare CRO’.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement